<DOC>
	<DOCNO>NCT02265744</DOCNO>
	<brief_summary>Study evaluate safety efficacy novel biologic treatment systemic lupus erythematosus male female adult . Patients qualify randomize either active BMS-931699 placebo initially , 24 week . Patients complete initial 24 week treatment respond therapy option continue receive BMS-931699 part long-term extension ( LTE ) . Disease activity safety assess course study laboratory value , various rating scale accept systemic lupus erythematosus study patient self reporting .</brief_summary>
	<brief_title>Safety Efficacy Study Biologic Treat Systemic Lupus Erythematosus</brief_title>
	<detailed_description>1 . Subjects complete Day 169 ( 24 week ) study medication may eligible enter optional LTE period 2 . The LTE period remain blind longer placebo arm : - Subjects remain originally assign treatment arm unless placebo - Subjects initially randomize placebo arm automatically re-randomized one exist active arm Day 169 ( 24 week )</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Male female age 18 70 ( include ) Diagnosed active systemic lupus erythematosus doctor Disease must patient 's joint skin minimum Taking medication allow exclude Diagnosed active lupus nephritis , multiple sclerosis rheumatoid arthritis Diagnosed active tuberculosis ongoing infection bacteria virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>